Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Marion McCourt; Executive Vice President - Commercial; Regeneron Pharmaceuticals Inc. Christopher Fenimore; Chief Financial Officer, Senior Vice President - Finance; Regeneron Pha ...

EYLEA HD is anticipated to gain traction with the launch of a prefilled syringe in mid-2025 and label expansions for macular edema and extended dosing intervals. Management believes these developments ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $12.07, up 2% year-over-year, beating the ...

Cox's net worth is $4.4 billion. #335 on the Forbes 400 List, Leonard Schleifer got his bachelor's degree from Cornell University before obtaining his M.D. and PhD from the University of Virginia.

Reports Q4 revenue $3.79B, consensus $3.75B. “Regeneron’s (REGN) financial and commercial strength allows for continued investment in our ...

The New York–based biotech Schleifer founded in 1988 has been much in the news this year for the drug, an antibody cocktail, it developed to fight COVID-19—and which was used in October to ...

Regeneron's CEO, Leonard Schleifer, once criticized arbitrary drug price increases by pharmaceutical companies. But in July, the company's eczema drug price increased by 3%. Regeneron said Sanofi ...

The CEO and co-founder of biotech firm, Regeneron, Leonard Schleifer earn and annual salary of $452 million, as per reports. Reed Hastings, the co-founder and executive chairman of streaming giant ...

Ahead of that presentation, Leonard Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron, stated: “The Regeneron name is synonymous with innovation ...